Payload Information
General Information of This Payload
| Payload ID | PAY0MKUNQ |
|||||
|---|---|---|---|---|---|---|
| Name | Pemetrexed |
|||||
| Synonyms |
PMX; Pemetrexed
Click to Show/Hide
|
|||||
| Target | Deoxyribonucleic acid (DNA) | |||||
| Formula | C20H21N5O6 |
|||||
| Isosmiles | O=C(NC(N)=N1)C2=C1NC=C2CCC3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)C=C3 |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1
|
|||||
| InChIKey |
WBXPDJSOTKVWSJ-ZDUSSCGKSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
427.417 |
Polar area |
191.26 |
||
Complexity |
1140.961628 |
xlogp Value |
0.6664 |
|||
Heavy Count |
31 |
Rot Bonds |
9 |
|||
Hbond acc |
6 |
Hbond Donor |
6 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cell-based Percent Inhibition (%) | -0.05 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -0.05 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -0.2 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -0.2 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -2.46 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -47.37 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -5.93 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 0 | % |
SW620 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 0 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 0 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 0.271 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 10.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 11.7 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 12.6 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 14 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 17 | % |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 17.3 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 21.8 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 22.93 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 27.16 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 27.5 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 27.89 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | <30 | % |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Cellular activity | 30.6 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 32.32 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 38.05 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 39.88 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 4.41 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 4.56 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 4.98 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 40 | % | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 43 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 45.8 | % |
SW620 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 46.4 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 47.1 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 47.8 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 49.1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 49.43 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | <50 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | <50 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | <50 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 50 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cell-based Percent Inhibition (%) | >=50 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | <50 | % |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
||
| Cell-based Percent Inhibition (%) | <50 | % |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
||
| Cell-based Percent Inhibition (%) | <50 | % |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
||
| Cell-based Percent Inhibition (%) | <50 | % |
BGC-823 cells
|
Stomach adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 50 | % |
BGC-823 cells
|
Stomach adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | <50 | % |
BGC-823 cells
|
Stomach adenocarcinoma
|
||
| Cellular activity | 54.2 | % |
SW620 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 56.2 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 58.67 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 60 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 60 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 61.82 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 61.95 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 64.42 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 64.6 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 67 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
Undisclosed | |
| Cellular activity | 7.5 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 72.11 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 74.73 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 75 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | >80 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cell-based Percent Inhibition (%) | >80 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 84.5 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 85 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | >=90 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | >=90 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 99.3 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 10 | nM |
HCC 2998 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 10.38 | nM |
786-O cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
U251 cells
|
Astrocytoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
Hs578T cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SK-OV-3 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SN12C cells
|
Renal cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SW620 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SK-MEL-2 cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
CAKI-1 cells
|
Clear cell renal cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SK-MEL-28 cells
|
Cutaneous melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SK-MEL-5 cells
|
Cutaneous melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SNB-19 cells
|
Astrocytoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
NCI-H226 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
NCI-H322M cells
|
Minimally invasive lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
OVCAR-5 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SNB-75 cells
|
Glioblastoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
BT-549 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
EKVX cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
HOP-92 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
KM12 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
M14 cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
Malme-3M cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
NCI-H522 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
OVCAR-4 cells
|
Ovarian adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
RXF 393 cells
|
Renal carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SR cells
|
Leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
TK-10 cells
|
Renal carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
UACC-257 cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
MDA-N cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 102 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 102 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 10303.86 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 104 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.74 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.74 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 11000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 110000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 110000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 110000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1260 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1260 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1260 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 13.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 13.2 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 13.2 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 13.2 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 13.2 | nM |
CHO cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 138 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 138 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 138 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 138 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 138 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 138 | nM |
CHO cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 138 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 138 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 138 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 1396.37 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.01 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 14.69 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1400 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1400 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 14000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 14000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 15000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 15000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 15000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Cytotoxic Concentration (CC50) | 151160 | nM |
BEAS-2B cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15400 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Cytotoxic Concentration (CC50) | 15490 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 16 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1730 | nM |
HUVEC cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 19000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 19000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >19952.62 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 20000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 20000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 20000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 203.96 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2040 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2070 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2090 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2130 | nM |
NCI-H1975 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22.2 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22.26 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 22.3 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Cytotoxic Concentration (CC50) | 22620 | nM |
GES1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 230.14 | nM |
UACC-62 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2300 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2300 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2300 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2300 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2300 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2300 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2300000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2300000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 25.53 | nM |
ACHN cells
|
Renal adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 25.82 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Cytotoxic Concentration (CC50) | 25370 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 254 | nM |
D4 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 254 | nM |
D4 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 254 | nM |
D4 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 254 | nM |
D4 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 254 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 26.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 269.77 | nM |
A498 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2800 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2800 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2800 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2800 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2800 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2800 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2800 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 281.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 29.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 290 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 29000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 29000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 29000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30.57 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 30.6 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 30000 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 3019.95 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Cytotoxic Concentration (CC50) | 30690 | nM |
L02 cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 3162.28 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Cytotoxic Concentration (CC50) | 321120 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 327 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 327 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 327 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 327 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 327 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 327 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3290 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3310 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 35.89 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3730 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 38000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 38000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 38000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 38000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3850 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 387.26 | nM |
SF268 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 388 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 388 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 388 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 388 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 39.4 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.94 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 417.83 | nM |
SF-295 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM |
CHO cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 430 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 430 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 430 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 430 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4350 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 46.6 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 460 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 460 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 460 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5120 | nM |
Calu-1 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5390 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5700 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5700 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 59.7 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
CHO cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
D4 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
D4 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
D4 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
D4 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 627 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 63.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 65.16 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 650 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 66.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6600 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6600 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6600 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6600 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6600 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6600 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6600 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6600 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 66000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 68 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 68 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 68 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 68 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 68 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 68 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 68 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 68 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 69.5 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 690 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6900 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6960 | nM |
SGC-7901 cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 70.2 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 71 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 71 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 74.3 | nM |
LOX IMVI cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 76000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 76000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 76000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 76000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 76000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 76000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 76000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 76000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 76000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 76000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 76000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 760000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 8.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
SW620 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 80.2 | nM |
SW620 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 849 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 863 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 8669.62 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 894 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 894 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 894 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 894 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 894 | nM |
CHO cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 894 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 894 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9.94 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.95 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 90 | nM |
SW620 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9080 | nM |
SGC-7901 cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 974 | nM |
R2 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 974 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 974 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 974 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 974 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.2818 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.2818 | uM | Undisclosed | Undisclosed | Undisclosed |
Each Antibody-drug Conjugate Related to This Payload